The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.

The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.

The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.

Disclosed are a Piper laetispicum extract and a preparation method therefor and a use thereof. The Piper laetispicum extract includes any one or more of sesamin, (2E,6E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)heptadienamide, (2E,4E)-N-isobutyldodecane-2,4-dieneamide, (2E,4E)-N-isobutyl-15-phenylpentadeca-2,4-dieneamide, (2E,4E,14Z)—N-isobutyleicosane-2,4,14-trienamide, and (2E,4E)-N-isobutyl-13-phenyltrideca-2,4-dieneamide. The Piper laetispicum extract can prevent depression.

A method of inhibiting growth of a bacterium including steps of: a) delivering a polynucleotide including a sequence of SEQ ID NO: 1 or a homologue thereof to the bacterium, and b) contacting the bacterium with an effective amount of an antibiotic; wherein the bacterium is Pseudomonas aeruginosa. A method of treating a subject suffering from an infection caused by a bacterium which is Pseudomonas aeruginosa and the method including steps of: i) delivering said polynucleotide to a tissue infected by the bacterium or a bacterial cell in the subject; and ii) administering an effective amount of an antibiotic to the subject. A composition and a recombinant plasmid containing said polynucleotide.